ATE458000T1 - Zielgerichtete fusionsproteine für die krebstherapie - Google Patents
Zielgerichtete fusionsproteine für die krebstherapieInfo
- Publication number
- ATE458000T1 ATE458000T1 AT06821700T AT06821700T ATE458000T1 AT E458000 T1 ATE458000 T1 AT E458000T1 AT 06821700 T AT06821700 T AT 06821700T AT 06821700 T AT06821700 T AT 06821700T AT E458000 T1 ATE458000 T1 AT E458000T1
- Authority
- AT
- Austria
- Prior art keywords
- moiety
- cancer
- apoptosis
- fusion proteins
- cell
- Prior art date
Links
- 102000037865 fusion proteins Human genes 0.000 title abstract 5
- 108020001507 fusion proteins Proteins 0.000 title abstract 5
- 238000011275 oncology therapy Methods 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 5
- 201000011510 cancer Diseases 0.000 abstract 5
- 108091005804 Peptidases Proteins 0.000 abstract 3
- 239000004365 Protease Substances 0.000 abstract 3
- 230000006907 apoptotic process Effects 0.000 abstract 3
- 102000035195 Peptidases Human genes 0.000 abstract 2
- 230000001640 apoptogenic effect Effects 0.000 abstract 2
- 230000001939 inductive effect Effects 0.000 abstract 2
- 101500027956 Homo sapiens Vasoactive intestinal peptide Proteins 0.000 abstract 1
- 102000028517 Neuropeptide receptor Human genes 0.000 abstract 1
- 108070000018 Neuropeptide receptor Proteins 0.000 abstract 1
- 102000013535 Proto-Oncogene Proteins c-bcl-2 Human genes 0.000 abstract 1
- 108010090931 Proto-Oncogene Proteins c-bcl-2 Proteins 0.000 abstract 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 1
- 102000055135 Vasoactive Intestinal Peptide Human genes 0.000 abstract 1
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 abstract 1
- 102000012088 Vasoactive Intestinal Peptide Receptors Human genes 0.000 abstract 1
- 108010075974 Vasoactive Intestinal Peptide Receptors Proteins 0.000 abstract 1
- 238000003776 cleavage reaction Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000011065 in-situ storage Methods 0.000 abstract 1
- VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000007017 scission Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Marine Sciences & Fisheries (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN3084DE2005 | 2005-11-18 | ||
| PCT/IN2006/000452 WO2007057922A1 (en) | 2005-11-18 | 2006-11-16 | Targeted fusion proteins for cancer therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE458000T1 true ATE458000T1 (de) | 2010-03-15 |
Family
ID=37772861
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06821700T ATE458000T1 (de) | 2005-11-18 | 2006-11-16 | Zielgerichtete fusionsproteine für die krebstherapie |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20100184651A1 (de) |
| EP (1) | EP1957524B1 (de) |
| AT (1) | ATE458000T1 (de) |
| AU (1) | AU2006314037B2 (de) |
| CA (1) | CA2630012A1 (de) |
| DE (1) | DE602006012358D1 (de) |
| WO (1) | WO2007057922A1 (de) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130172274A1 (en) | 2005-12-20 | 2013-07-04 | Duke University | Methods and compositions for delivering active agents with enhanced pharmacological properties |
| US8841255B2 (en) * | 2005-12-20 | 2014-09-23 | Duke University | Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides |
| WO2007073486A2 (en) | 2005-12-20 | 2007-06-28 | Duke University | Methods and compositions for delivering active agents with enhanced pharmacological properties |
| DE102007042107B4 (de) * | 2007-09-05 | 2010-07-15 | Siemens Ag | Pharmazeutische Zusammensetzung mit eisenbindendem Agens |
| WO2009139570A1 (en) * | 2008-05-14 | 2009-11-19 | Kyungpook National University Industry-Academic Cooperation Foundation | Peptides for targeting apoptotic cells and uses thereof |
| CN102131516B (zh) | 2008-06-27 | 2016-03-16 | 杜克大学 | 包含弹性蛋白样肽的治疗剂 |
| TWI435875B (zh) * | 2008-07-08 | 2014-05-01 | Daiichi Sankyo Co Ltd | 含氮芳香族雜環化合物 |
| US9029505B2 (en) * | 2009-08-14 | 2015-05-12 | Phasebio Pharmaceuticals, Inc. | Modified vasoactive intestinal peptides |
| CN103561771B (zh) | 2011-03-17 | 2019-01-04 | 伯明翰大学 | 重新定向的免疫治疗 |
| CA2873553C (en) | 2011-06-06 | 2020-01-28 | Phasebio Pharmaceuticals, Inc. | Use of modified vasoactive intestinal peptides in the treatment of hypertension |
| GB201203442D0 (en) | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
| WO2015134833A2 (en) * | 2014-03-07 | 2015-09-11 | Proda Biotech Llc | Therapeutic proteins for treating cancers and methods for using such proteins |
| US11052132B2 (en) | 2014-05-08 | 2021-07-06 | Phasebio Pharmaceuticals, Inc. | Methods and compositions for treating cystic fibrosis |
| US10441649B2 (en) | 2015-02-02 | 2019-10-15 | The University Of Birmingham | Targeting moiety peptide epitope complexes having a plurality of T-cell epitopes |
| CN114652817B (zh) | 2015-02-09 | 2026-04-17 | 费斯生物制药公司 | 用于治疗肌肉疾病和病症的方法和组合物 |
| FI3377103T4 (fi) | 2015-11-19 | 2025-04-16 | Revitope Limited | Funktionaalinen vasta-ainefragmenttikomplementointi kaksikomponenttiselle järjestelmälle epätoivottujen solujen uudelleenohjattua tappamista varten |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6803358B1 (en) * | 2000-04-14 | 2004-10-12 | Twinstrand Therapeutics Inc. | Ricin-like toxin variants for treatment of cancer, viral or parasitic infections |
| AU7023798A (en) * | 1997-04-30 | 1998-11-24 | De Novo Enzyme Corporation | Ricin-like toxin variants for treatment of cancer, viral or parasitic infections |
| US20040171809A1 (en) * | 2002-09-09 | 2004-09-02 | Korsmeyer Stanley J. | BH3 peptides and method of use thereof |
| AU2006227816B2 (en) * | 2005-03-15 | 2012-04-05 | Allergan, Inc. | Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems |
-
2006
- 2006-11-16 AT AT06821700T patent/ATE458000T1/de not_active IP Right Cessation
- 2006-11-16 WO PCT/IN2006/000452 patent/WO2007057922A1/en not_active Ceased
- 2006-11-16 CA CA002630012A patent/CA2630012A1/en not_active Abandoned
- 2006-11-16 EP EP06821700A patent/EP1957524B1/de active Active
- 2006-11-16 AU AU2006314037A patent/AU2006314037B2/en not_active Ceased
- 2006-11-16 US US12/093,697 patent/US20100184651A1/en not_active Abandoned
- 2006-11-16 DE DE602006012358T patent/DE602006012358D1/de active Active
Also Published As
| Publication number | Publication date |
|---|---|
| DE602006012358D1 (de) | 2010-04-01 |
| EP1957524A1 (de) | 2008-08-20 |
| AU2006314037A1 (en) | 2007-05-24 |
| US20100184651A1 (en) | 2010-07-22 |
| AU2006314037B2 (en) | 2010-09-23 |
| WO2007057922A1 (en) | 2007-05-24 |
| EP1957524B1 (de) | 2010-02-17 |
| CA2630012A1 (en) | 2007-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE458000T1 (de) | Zielgerichtete fusionsproteine für die krebstherapie | |
| BR112013029525A8 (pt) | Proteínas de fusão terapêuticas | |
| AU2015269210A8 (en) | Methods of constructing amino terminal immunoglobulin fusion proteins and compositions thereof | |
| PL397167A1 (pl) | Przeciwnowotworowe bialko fuzyjne | |
| MX2009013372A (es) | Proteinas de fusion bifuncionales de la hormona estimulante de alfa-melanocitos (alfa-msh) y proteina natriuretica atrial (anp) y usos en hipertension y lesion de riñon aguda. | |
| JP2016538240A5 (de) | ||
| CY1122794T1 (el) | Συνθεσεις αλφα-γαλακτοσιδασης | |
| BR112017009951A2 (pt) | composições conjugadas direcionadas de xten e métodos de sua produção | |
| JP2016525551A5 (de) | ||
| MX2007013626A (es) | Anticuerpos dirigidos contra el peptido beta amiloide y procedimientos que usan los mismos. | |
| GEP20115324B (en) | Tweak binding antibodies | |
| RU2016135239A (ru) | Субстраты матриптазы и u-активатора плазминогена и другие расщепляемые остатки и способы их применения | |
| EA200700391A1 (ru) | Комбинированное лечение с применением слитых белков трансферрина, содержащих glp-1 | |
| NI201200134A (es) | Polipéptidos agonistas que se enlazan a dr5 | |
| PE20091713A1 (es) | Inhibicion del receptor para la proteina estimulante del macrofago (ron), composiciones y metodos | |
| MX2009003126A (es) | Agente para prevenir/tratar el cancer. | |
| PE20211272A1 (es) | POLIPEPTIDOS DE IL-22 Y PROTEINAS DE FUSION DE IL-22 Fc Y METODOS DE USO | |
| US20230174666A1 (en) | Anti-cd26 proteins and uses thereof | |
| EP2403871A4 (de) | Für missgefaltetes prionenprotein spezifische antikörper und epitope | |
| UY30324A1 (es) | Proteinas de fusion del rage, formulaciones y métodos de uso | |
| CL2012000063A1 (es) | Polipéptido factor ix (fix) o un fragmento del mismo porque comprende la modificación de un aminoácido; vector; célula; método para expresar el polipéptido fix; composición farmacéutica; uso de la composición para tratar enfermedades trombóticas, hemorrágicas y coagulación intravascular diseminada (cid) (div. sol. 1796-07). | |
| EP2352523A4 (de) | Verbesserte anti-cd19-antikörper | |
| TW201613958A (en) | MIC-1 fusion proteins and uses thereof | |
| PE20090225A1 (es) | Proteinas de fusion que degradan el peptido beta amiloide | |
| PE20081546A1 (es) | Antagonistas del dr6 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |